Sign in or Register   Sign in or Register
  |  

Mouse Anti-MAP4K1 Recombinant Antibody (CBFYH-2633) (CBMAB-H3674-FY)

This product is mouse antibody that recognizes MAP4K1. The antibody CBFYH-2633 can be used for immunoassay techniques such as: WB, IP.
See all MAP4K1 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBFYH-2633
Antibody Isotype
IgG1
Application
WB, IP

Basic Information

Immunogen
Recombinant human protein purified from E.coli
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
HEPES, 0.15M NaCl, 0.01% BSA, 50% glycerol
Preservative
0.03% Sodium azide
Concentration
2 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
mitogen-activated protein kinase kinase kinase kinase 1
Introduction
MAP4K1 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1) is a Protein Coding gene. Among its related pathways are Kit receptor signaling pathway and TGF-Beta Pathway. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is MAP4K5.
Entrez Gene ID
11184
UniProt ID
Q92918
Alternative Names
Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1; Hematopoietic Progenitor Kinase 1; MAPK/ERK Kinase Kinase Kinase 1; MEK Kinase Kinase 1; EC 2.7.11.1; MEKKK 1; HPK1; Hematopoietic Progenitor Kinase; EC 2.7.11
Function
Serine/threonine-protein kinase, which may play a role in the response to environmental stress (PubMed:24362026).
Appears to act upstream of the JUN N-terminal pathway (PubMed:8824585).
May play a role in hematopoietic lineage decisions and growth regulation (PubMed:8824585, PubMed:24362026).
Able to autophosphorylate (PubMed:8824585).
Together with CLNK, it enhances CD3-triggered activation of T-cells and subsequent IL2 production (By similarity).
Biological Process
Cell population proliferationManual Assertion Based On ExperimentIMP:UniProtKB
Cellular response to phorbol 13-acetate 12-myristateManual Assertion Based On ExperimentIDA:UniProtKB
JNK cascadeManual Assertion Based On ExperimentIDA:UniProtKB
Peptidyl-serine phosphorylationManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of MAPK cascadeManual Assertion Based On ExperimentIDA:UniProtKB
Protein autophosphorylationManual Assertion Based On ExperimentIDA:UniProtKB
Protein phosphorylationManual Assertion Based On ExperimentIDA:UniProtKB
Cellular Location
Membrane
PTM
Autophosphorylates: phosphorylation promotes ubiquitination by the Cul7-RING(FBXW8) ubiquitin-protein ligase complex, leading to its degradation by the proteasome.
Tyrosine-phosphorylated after activation of hemopoietic cells.
Ubiquitinated by the Cul7-RING(FBXW8) ubiquitin-protein ligase complex following autophosphorylation, leading to its degradation by the proteasome.

Knight, T. E., Edwards, H., Taub, J. W., & Ge, Y. (2021). MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition. EBioMedicine, 70.

He, T. S., Huang, J., Chen, T., Zhang, Z., Cai, K., Yu, J., & Xu, L. G. (2021). The Kinase MAP4K1 Inhibits Cytosolic RNA-Induced Antiviral Signaling by Promoting Proteasomal Degradation of TBK1/IKKε. Microbiology Spectrum, 9(3), e01458-21.

Ling, Q., Li, F., Zhang, X., Mao, S., Lin, X., Pan, J., ... & Jin, J. (2021). MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway. EBioMedicine, 69.

Faia, K., Toso, A., Fetalvero, K., Roche, M., Bench, S., O'Hearn, E., ... & Brubaker, J. (2021). MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models. Cancer Research, 81(13_Supplement), 1717-1717.

Leder, G., Carretero, R., Mowat, J., Berndt, S., Neuhaus, R., Font, N. A., ... & Offringa, R. (2021). Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1. Cancer Research, 81(13_Supplement), 1722-1722.

Wu, Q., Ma, J., Meng, W., & Hui, P. (2020). DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1. Cancer Biology & Therapy, 21(1), 17-25.

Bai, Y., Liu, X., Qi, X., Liu, X., Peng, F., Li, H., ... & Shao, S. (2019). PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway. EBioMedicine, 42, 311-325.

Lei, J. J., Li, H. Q., Mo, Z. H., Liu, K. J., Zhu, L. J., Li, C. Y., ... & Zhang, L. (2019). Long noncoding RNA CDKN2B‐AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription. The FASEB Journal, 33(6), 7037-7048.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MAP4K1 Recombinant Antibody (CBFYH-2633)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare